Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017426 | 0.88 | RAB9A (0.52) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL8237785 | 0.86 | HDAC6 (0.43) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC2 | |
| SCHEMBL9883399 | 0.86 | HPGD (0.50) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL26186317 | 0.79 | HDAC1 (0.48) | HPGDSMN1; SMN2ALDH1A1HDAC1HDAC6 | |
| SCHEMBL6769761 | 0.78 | HPGDS (0.70) | HPGDSKCNH2USP30 | |
| SCHEMBL12295616 | 0.77 | HDAC1 (0.45) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL15341327 | 0.76 | ALDH1A1 (0.42) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC2 | |
| SCHEMBL9883383 | 0.76 | SMN1; SMN2 (0.43) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC1 | |
| SCHEMBL12295671 | 0.76 | HDAC3 (0.54) | HPGDSHPGDSMN1; SMN2ALDH1A1HDAC2 | |
| SCHEMBL29115498 | 0.75 | HPGDS (0.63) | HPGDSHPGDSMN1; SMN2ALDH1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426416-B2 | Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-04-23 | — | — | US | disclosed |
| US-20110237585-A1 | SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-29 | — | — | US | disclosed |
| US-7947830-B2 | Substituted propenyl piperazine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7888360-B2 | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-02-15 | — | — | US | disclosed |
| US-7884105-B2 | 2-(N'-2-amino-3,4-dioxocyclobutenyl)-N-piperazinyl)-pyrimidine-5-hydroxamic acid derivatives; antiproliferative, anticarcinogenic, and antitumor agents; psoriasis; skin, respiratory system, psychological, and genetic disorders; transplant rejection; Alzheimer's and Parkinson's disease; vision defects | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-02-08 | — | — | US | disclosed |
| US-20090036463-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20080255140-A1 | Squaric Acid Derivatives as Inhibitors of Histone Deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-16 | — | — | US | disclosed |
| US-20070135424-A1 | SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN-CILAG (BE) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036463-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | HPGDS 906/4885HPGD 323/4885SMN1; SMN2 4233/4885 |
| US-20080255140-A1 | Squaric Acid Derivatives as Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | HPGDS 1200/4885HPGD 480/4885SMN1; SMN2 2175/4885 |
| US-20070135424-A1 | SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC2 | HPGDS 1393/4885HPGD 734/4885SMN1; SMN2 4065/4885 |
| US-20110237585-A1 | SUBSTITUTED PROPENYL PIPERAZINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC2 | HPGDS 1393/4885HPGD 734/4885SMN1; SMN2 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.